Literature DB >> 709474

Impaired serum antibody response to inactivated influenza A and B vaccine in cancer patients.

H G Stiver, B H Weinerman.   

Abstract

The serum antibody response to vaccination with bivalent inactivated influenza vaccine containing A/Port Chalmers/1/73 (H3N2) and B/Hong Kong/5/72 antigens was assessed in 44 patients with cancer and in 27 healthy control subjects. A fourfold or greater increase in antibody titre after vaccination occurred in 16 of the 44 cancer patients and 25 of the 27 controls for the A antigen, and in 14 of the 44 cancer patients and 20 of the 27 controls for the B antigen. Patients with lymphoma, who tended to have hypogammaglobulinemia, responded less well than did patients with solid tumours. Among the latter the failure to show a fourfold or greater increase in antibody titre correlated with a poorer 18-month survival.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 709474      PMCID: PMC1818783     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  13 in total

1.  PRODUCTION OF ANTIBODIES AGAINST VIRUSES IN LEUKAEMIA AND RELATED DISEASES.

Authors:  R B HEATH; G H FAIRLEY; J S MALPAS
Journal:  Br J Haematol       Date:  1964-07       Impact factor: 6.998

2.  Observations on excess mortality associated with epidemic influenza.

Authors:  T C EICKHOFF; I L SHERMAN; R E SERFLING
Journal:  JAMA       Date:  1961-06-03       Impact factor: 56.272

3.  Nonspecific protection of mice against influenza virus infection by local or systemic immunization with Bacille Calmette-Guérin.

Authors:  J C Spencer; R Ganguly; R H Waldman
Journal:  J Infect Dis       Date:  1977-08       Impact factor: 5.226

4.  Impaired serum antibody response to inactivated influenza A and B vaccine in renal transplant recipients.

Authors:  H G Stiver; P Graves; G Meiklejohn; G Schröter; T C Eickhoff
Journal:  Infect Immun       Date:  1977-06       Impact factor: 3.441

5.  Efficacy of "Hong Kong" vaccine in preventing "England" variant influenza A in 1972.

Authors:  H G Stiver; P Graves; T C Eickhoff; G Meiklejohn
Journal:  N Engl J Med       Date:  1973-12-13       Impact factor: 91.245

6.  The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses.

Authors:  D Hobson; R L Curry; A S Beare; A Ward-Gardner
Journal:  J Hyg (Lond)       Date:  1972-12

7.  Influenza immunization of adult patients with malignant diseases.

Authors:  D W Ortbals; H Liebhaber; C A Presant; A L Van Amburg; J Y Lee
Journal:  Ann Intern Med       Date:  1977-11       Impact factor: 25.391

8.  Influenza in children and young adults with cancer: 20 cases.

Authors:  S Feldman; R G Webster; M Sugg
Journal:  Cancer       Date:  1977-01       Impact factor: 6.860

9.  Influenza vaccination and mortality from bronchopneumonia in the elderly.

Authors:  C H Howells; C K Vesselinova-Jenkins; A D Evans; J James
Journal:  Lancet       Date:  1975-02-15       Impact factor: 79.321

10.  Immunization with influenza vaccine in patients with haematological malignant disease.

Authors:  B J Feery; J R Sullivan; T H Hurley; M G Evered
Journal:  Med J Aust       Date:  1977-02-26       Impact factor: 7.738

View more
  14 in total

Review 1.  Influenza vaccines: from surveillance through production to protection.

Authors:  Pritish K Tosh; Robert M Jacobson; Gregory A Poland
Journal:  Mayo Clin Proc       Date:  2010-01-29       Impact factor: 7.616

Review 2.  Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses.

Authors:  Ken M Kunisaki; Edward N Janoff
Journal:  Lancet Infect Dis       Date:  2009-08       Impact factor: 25.071

3.  Antibody response to a two-dose influenza vaccine regimen in adult lymphoma patients on chemotherapy.

Authors:  W Lo; E Whimbey; L Elting; R Couch; F Cabanillas; G Bodey
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-10       Impact factor: 3.267

4.  Immunogenicity of an inactivated monovalent 2009 influenza A (H1N1) vaccine in patients who have cancer.

Authors:  Yiqing Xu; Nanda Methuku; Praveena Coimbatore; Theresa Fitzgerald; Yiwu Huang; Ying-Yi Xiao; Murali Pagala; Shachi Gupta; William Solomon; Philip Rubin; John Treanor; Alan Astrow; Howard Minkoff; Jay S Cooper
Journal:  Oncologist       Date:  2012-01-12

Review 5.  Influenza vaccination in children being treated with chemotherapy for cancer.

Authors:  Ginette M Goossen; Leontien C M Kremer; Marianne D van de Wetering
Journal:  Cochrane Database Syst Rev       Date:  2013-08-01

Review 6.  Use of licensed vaccines for active immunization of the immunocompromised host.

Authors:  L A Pirofski; A Casadevall
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

7.  A prospective study of the factors shaping antibody responses to the AS03-adjuvanted influenza A/H1N1 vaccine in cancer outpatients.

Authors:  Andreas F Hottinger; Anne-Claude C George; Michael Bel; Laurence Favet; Christophe Combescure; Sara Meier; Stéphane Grillet; Klara Posfay-Barbe; Laurent Kaiser; Claire-Anne Siegrist; Pierre-Yves Dietrich
Journal:  Oncologist       Date:  2012-02-21

8.  Immunogenicity and safety of high-dose trivalent inactivated influenza vaccine compared to standard-dose vaccine in children and young adults with cancer or HIV infection.

Authors:  Hana Hakim; Kim J Allison; Lee-Ann Van de Velde; Li Tang; Yilun Sun; Patricia M Flynn; Jonathan A McCullers
Journal:  Vaccine       Date:  2016-04-26       Impact factor: 3.641

Review 9.  The treatment of influenza with antiviral drugs.

Authors:  Grant Stiver
Journal:  CMAJ       Date:  2003-01-07       Impact factor: 8.262

10.  Immunogenicity and acceptance of influenza A (H1N1) vaccine in a cohort of chronic hepatitis C patients receiving pegylated-interferon treatment.

Authors:  Manuel Hernández-Guerra; Yanira González-Méndez; Patricia de Molina; Antonio Z Gimeno-García; Marta Carrillo; Carlos Casanova; Tomás Pumarola; Alejandro Jimenez; Miriam Hernández-Porto; Alvaro Torres; Enrique Quintero
Journal:  PLoS One       Date:  2012-11-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.